Log In
Print
BCIQ
Print
Print this Print this
 

3C23K

  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
DescriptionMAb targeting anti-Mullerian hormone receptor type II (AMHR2)
Molecular Target Anti-Mullerian hormone receptor type II (AMHR2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationOvarian cancer
Indication DetailsTreat ovarian cancer
Regulatory Designation
Partner GamaMabs Pharma S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today